Skip to main content

Table 1 Demographic, clinical, and behavioral data of study participants with microbiome data

From: The neovaginal microbiome of transgender women post-gender reassignment surgery

Variable

Variable category

Transgender women—neovaginal samples (n = 5)a

Transgender women—rectal samples (n = 7)a

Cisgender women—vaginal samples (n = 30)b

Age (median, range)

 

48 (28–57)

48 (35–57)

31 (19–55)

Time since first neovaginoplasty (median, range)

Years

9.5 (3.7–35.7)

10.9 (5.1–35.7)

NA

Time since most recent neovaginoplasty (median, range)

Years

9.5 (3.5–34)

9.5 (1.5–34)

NA

Surgery method—all techniques (n, %)

Penile inversion, scrotal cutaneous graft

4 (80)

4 (57)

NA

Penile inversion, scrotal cutaneous graft with sigmoid colon extension

1 (20)

3 (43)

Total number of surgeries (median, range)c

 

1 (1–4)

2 (1–6)

NA

Vaginal complaints (n, %)d

 

2 (40)

3 (43)

13 (43)

Number who practice vaginal washing (n, %)

 

1 (20)

1 (20)

1 (3.3)

Hormone therapy (n, %)e

Estrogen therapy/hormonal contraception

3 (60)

5 (71)

11 (37)

Not currently on therapy/hormonal contraception

1 (20)

1 (14)

16 (53)

Unknown

1 (20)

1 (14)

3 (10)

STI (n, %) f

Hepatitis B

4 (80)

5 (71)

Data not collected

Hepatitis C

0 (0)

0 (0)

Data not collected

Active syphilis

0 (0)

1 (14)

Data not collected

Anal chlamydia

0 (0)

2 (29)

Data not collected

Vaginal chlamydia

0 (0)

1 (14)

1 (3.3)

Anal gonorrhea

1 (20)

0 (0)

Data not collected

Vaginal gonorrhea

0 (0)

0 (0)

0

HIV

0 (0)

0 (0)

2 (6.7)

Sexually active in 30 days prior to sample collection (n, %)g

Reported receptive anal sex

1 (20)

3 (43)

NA

Reported receptive neovaginal sex

2 (40)

4 (57)

NA

Reported cis vaginal sex

NA

NA

19 (63)

Condom use in the last 30 days (n, %) h

 

0 (0)

0 (0)

7 (23)

Number of sexual partners in the last 30 days (median, range)

 

1 (0–1)

1 (0–1)

Data not collected

Applied a chemical substance (n, %)i

 

2 (40)

2 (29)

Data not collected

Used sex toy in vagina (n, %)

 

2 (40)

1 (14)

Data not collected

  1. aNine transgender women (TW) had both neovaginal and rectal samples collected for metaproteomics, but only 5 neovaginal samples and 7 rectal samples had bacterial proteins detected
  2. bA total of 32 samples from 30 cisgender women (CW) were collected. Two samples were longitudinal from the same Swedish participants
  3. cReasons for re-operation included stenosis, procedural complications, dissatisfaction with external appearance, anorgasmia, and sexual mismatch
  4. dVaginal complaints included spontaneous pain, pain during intercourse, spontaneous bleeding, fetid odor and/or vaginal depth amongst TW, and vaginal discomfort, discharge, itching, pain, bleeding, and odor amongst CW
  5. eCW reported using either oral contraceptive pills, injectable contraception, vaginal ring contraception, or a hormonal intrauterine device
  6. fAll STIs were tested for at the time of sample collection. Hepatitis B seropositivity represented past exposure
  7. gIncludes instances of neovaginal and/or anal intercourse for TW and penetrative vaginal intercourse for CW
  8. hIndicates condom use in any sexual activities (anal and neovaginal intercourse included) in the 30 days prior to sample collection
  9. iChemical substances included lubricants, soap, and/or douche
Back to article page

Microbiome

ISSN: 2049-2618

Contact us